TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23218100

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: All atypical antipsychotics
Number of subjects: 332
Study: 21949049

Group type: EXPERIMENTAL
Intervention: High-SFA (HS) diet for 4 weeks
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Reference (HS), high-MUFA (HM), or low-fat (LF) diet for 24 weeks
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: P:S ratio ≤ 0.33
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Increasing P:S ratio (≤0.33 to >0.65; 0.34 to >0.65)
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: P:S × genotype interaction
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: PPARG Ala12 allele carriers
Number of subjects: 367
Study: 18688547

Group type: EXPERIMENTAL
Intervention: 1 mg/kg/day iron supplement
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: 2 mg/kg/day iron supplement
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: 25 mg/week iron supplement
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control (no supplementation)
Number of subjects: 114
Study: 16941319

Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate 4% detergent (CHG)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Propan‐2‐OL (70% by volume; Iso 70)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ethanol 85% (E 85)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Propan‐1‐OL (N 60) - reference disinfection procedure
Number of subjects: 20
Study: 15246630

Group type: EXPERIMENTAL
Intervention: HPV16 L1 virus-like particle vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11704601

Group type: EXPERIMENTAL
Intervention: Inhaled steroids alone or associated with oral steroids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Steroid-untreated asthmatics
Number of subjects: 0
Study: 9449059

Group type: EXPERIMENTAL
Intervention: 235 to 250 lux treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: less than 1 lux treatment
Number of subjects: 0
Study: 8493453

Group type: EXPERIMENTAL
Intervention: Allopurinol (50 mg by mouth 4 times a day)
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: DMSO (500 mg by mouth 4 times a day)
Number of subjects: 306

Group type: COMPARATOR
Intervention: Control group (electrocoagulation of liver secondaries alone)
Number of subjects: 306
Study: 3307367

Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 107

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 107
Study: 31676585

Group type: EXPERIMENTAL
Intervention: Magic therapy intervention group (n = 47)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Magic therapy intervention group (n = 34)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Health professionals (n = 37 total: 9 physicians, 8 nurses, 20 pediatric residents)
Number of subjects: 190
Study: 27287251

Group type: EXPERIMENTAL
Intervention: Post-procedural anticoagulation (unfractionated or low-molecular-weight heparins or fondaparinux)
Number of subjects: 5239

Group type: COMPARATOR
Intervention: No post-procedural anticoagulation
Number of subjects: 5239
Study: 26063319

Group type: EXPERIMENTAL
Intervention: Deep needling on bilateral ST25 (group A)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Shallow needling on bilateral ST25 (group B)
Number of subjects: 96
Study: 23529145

Group type: EXPERIMENTAL
Intervention: Standard rehabilitation plus strength training (Train)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Standard rehabilitation (Control)
Number of subjects: 51
Study: 21794899

Group type: EXPERIMENTAL
Intervention: Desirudin 15 mg SC twice daily
Number of subjects: 120

Group type: COMPARATOR
Intervention: Heparin 5000 units SC thrice daily
Number of subjects: 120
Study: 19317886

Group type: EXPERIMENTAL
Intervention: LEV XR 1,000 mg/day
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study: 16836555

Group type: EXPERIMENTAL
Intervention: Acute normovolemic hemodilution (ANH)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Standard transfusion
Number of subjects: 155
Study: 12952114

Group type: EXPERIMENTAL
Intervention: Environmental control (EC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Unchanged environment (UE)
Number of subjects: 40
Study: 10711866

Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.04 mg/kg twice a day for 2 days
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Dexamethasone 1.0 mg/kg twice a day for 2 days
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 9377855

Group type: EXPERIMENTAL
Intervention: Carboplatin (CBDCA) AUC 5.5-11 (400-800 mg/m2), Cyclophosphamide (CTX) 1500-2500 mg/m2, Etoposide (VP-16) 450-550 mg/m2, G-CSF 5 mg/kg/day from day 4 to day 17, Thymopentin (TP5) 1 mg/kg on alternate days from day 4 to day 30
Number of subjects: 12
Study: 7794289

Group type: EXPERIMENTAL
Intervention: Autohaler Inhalation Device (breath-activated MDI)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard MDI
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Autohaler
Number of subjects: 20
Study: 3898835

Group type: EXPERIMENTAL
Intervention: Sucralfate administered every six hours
Number of subjects: 155

Group type: COMPARATOR
Intervention: Antacid given hourly
Number of subjects: 155
Study: 29926012

Group type: EXPERIMENTAL
Intervention: Mannitol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Furosemide
Number of subjects: 0
Study: 27229709

Group type: EXPERIMENTAL
Intervention: Endoscopic submucosal dissection (ESD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Endoscopic mucosal resection (EMR)
Number of subjects: 0
Study: 24814479

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (600 mg)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Diesel exhaust with N-acetylcysteine
Number of subjects: 26

Group type: COMPARATOR
Intervention: Diesel exhaust with placebo
Number of subjects: 26
Study: 22697448

Group type: EXPERIMENTAL
Intervention: Guiando a Niños Activos (GANA)
Number of subjects: 58

Group type: COMPARATOR
Intervention: standard PCIT
Number of subjects: 58

Group type: COMPARATOR
Intervention: treatment as usual (TAU)
Number of subjects: 58
Study: 20721516

Group type: COMPARATOR
Intervention: Room air
Number of subjects: 15

Group type: COMPARATOR
Intervention: Hypoxia
Number of subjects: 15

Group type: COMPARATOR
Intervention: CO25%
Number of subjects: 15

Group type: COMPARATOR
Intervention: Rest
Number of subjects: 15

Group type: COMPARATOR
Intervention: Hypoxia exercise
Number of subjects: 15
Study: 18831606

Group type: EXPERIMENTAL
Intervention: Brake dynamics manipulated such that deceleration was proportional to pedal position
Number of subjects: 2

Group type: COMPARATOR
Intervention: Brake dynamics manipulated such that deceleration was proportional to both pedal position and current speed
Number of subjects: 2
Study: 15972451

Group type: EXPERIMENTAL
Intervention: Aspirin (75 mg/d orally) for 14 days
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Aspirin (150 mg/day) for hypercholesterolemics
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo for 14 days
Number of subjects: 2
Study: 12194391

Group type: EXPERIMENTAL
Intervention: MEMBRANE IN SYRINGE technique
Number of subjects: 20
Study: 12485551

Group type: EXPERIMENTAL
Intervention: Delayed antibiotic prescriptions
Number of subjects: 26
Study: 10036599

Group type: EXPERIMENTAL
Intervention: Desogestrel 75 micrograms/day
Number of subjects: 989

Group type: COMPARATOR
Intervention: Levonorgestrel 30 micrograms/day
Number of subjects: 989
Study: 7984540

Group type: EXPERIMENTAL
Intervention: Diltiazem 300 mg/d
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg/d
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Combination of Diltiazem 300 mg and Enalapril 20 mg
Number of subjects: 176
Study: 3140687

Group type: EXPERIMENTAL
Intervention: Methohexital (M)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Thiopental (T)
Number of subjects: 40
Study: 30999110

Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 1489

Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 1489
Study: 28601101

Group type: EXPERIMENTAL
Intervention: Not‐on‐Tobacco (N‐O‐T)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Not‐on‐Tobacco with a physical activity module (N‐O‐T+FIT)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Brief Intervention (BI)
Number of subjects: 232
Study: 25432415

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day for 16 weeks
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/extended-release (ER) niacin 2 g/day
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Fenofibric acid 135 mg
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: ER niacin 2 g/day added to atorvastatin 10 mg
Number of subjects: 163
Study: 22684982

Group type: EXPERIMENTAL
Intervention: Parent-based behavioral counseling (6 sessions over 3 months)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Standard care control group
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 135
Study: 21911844

Group type: EXPERIMENTAL
Intervention: Progress-framed story
Number of subjects: 175

Group type: COMPARATOR
Intervention: Disparity-framed story
Number of subjects: 175
Study: 18057052

Group type: EXPERIMENTAL
Intervention: Salmeterol (50 microg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 17017486

Group type: EXPERIMENTAL
Intervention: Hormonal replacement therapy (HRT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selective estrogen receptor modulators (SERMs)
Number of subjects: 0
Study: 12971707

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (1 hour, three times weekly)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (medical treatment only)
Number of subjects: 40
Study: 10949773

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 8939232

Group type: EXPERIMENTAL
Intervention: 15.0 g iodine diluted 1:1
Number of subjects: 138

Group type: COMPARATOR
Intervention: 15.0 g iodine undiluted
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: 22.5 g iodine diluted 1:1
Number of subjects: 138

Group type: COMPARATOR
Intervention: 15.0 g iodine diluted 3:1
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Iodine concentration (varied)
Number of subjects: 138
Study: 1348161

Group type: EXPERIMENTAL
Intervention: Haloperidol and alprazolam
Number of subjects: 28

Group type: COMPARATOR
Intervention: Haloperidol with placebo
Number of subjects: 28
Study: 30353590

Group type: EXPERIMENTAL
Intervention: 75 g/kg S‐DDGS
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 150 g/kg S‐DDGS
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 225 g/kg S‐DDGS
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 300 g/kg S‐DDGS
Number of subjects: 200

Group type: COMPARATOR
Intervention: 0 g/kg S‐DDGS (control)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Increasing S‐DDGS
Number of subjects: 200
Study: 29471147

Group type: EXPERIMENTAL
Intervention: Blue light PDT (400 nm)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Red light PDT (635 nm)
Number of subjects: 3
Study: 26792796

Group type: EXPERIMENTAL
Intervention: Social Stories™ intervention (goal-setting session followed by a manualised toolkit for creating Social Stories)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Attention control (goal-setting session followed by attention control)
Number of subjects: 50
Study: 24708660

Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (Ferinject®)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Normal (0.9%) saline (placebo)
Number of subjects: 450
Study: 22967500

Group type: EXPERIMENTAL
Intervention: Insulin infusion (7-hour duration)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Saline infusion (7-hour duration)
Number of subjects: 18
Study: 20419963

Group type: EXPERIMENTAL
Intervention: Continuous closure technique using 5/0 proline double ended suture
Number of subjects: 60

Group type: COMPARATOR
Intervention: Interrupted closure technique using 5/0 prolene double ended sutures
Number of subjects: 60
Study: 19223671

Group type: EXPERIMENTAL
Intervention: Compression garments
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (no garments)
Number of subjects: 14
Study: 15937294

Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg) administered via three infusions at Weeks 0, 2, and 6
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo infusions
Number of subjects: 22
Study: 12371908

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 10367949

Group type: EXPERIMENTAL
Intervention: Booster vaccination with recombinant hepatitis B vaccine
Number of subjects: 41

Group type: COMPARATOR
Intervention: Reference group receiving standard three-dose vaccination (0, 1, and 6 months)
Number of subjects: 41
Study: 7675948

Group type: EXPERIMENTAL
Intervention: diazepam 5 mg
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: diazepam 10 mg
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: alprazolam 0.5 mg
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: nitrazepam 5 mg
Number of subjects: 145

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 145
Study: 2041051

Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 21

Group type: COMPARATOR
Intervention: Nonintervention diet
Number of subjects: 21
Study: 7272161

Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg four times daily)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 30429050

Group type: EXPERIMENTAL
Intervention: Phased withdrawal of heart failure medications
Number of subjects: 51

Group type: COMPARATOR
Intervention: Continuation of heart failure medications
Number of subjects: 51

Group type: COMPARATOR
Intervention: Continuation of heart failure medications (after initial 6 months)
Number of subjects: 51
Study: 27723271

Group type: EXPERIMENTAL
Intervention: Baricitinib monotherapy (4 mg once daily)
Number of subjects: 588

Group type: EXPERIMENTAL
Intervention: Combination of baricitinib and MTX
Number of subjects: 588

Group type: COMPARATOR
Intervention: MTX monotherapy (once weekly)
Number of subjects: 588

Group type: EXPERIMENTAL
Intervention: Baricitinib plus MTX
Number of subjects: 588

Group type: COMPARATOR
Intervention: MTX monotherapy
Number of subjects: 588

Group type: EXPERIMENTAL
Intervention: Baricitinib monotherapy
Number of subjects: 588
Study: 26685691

Group type: EXPERIMENTAL
Intervention: HA injections (3 injections, one every 2 weeks)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Exercise-based rehabilitation (20 treatment sessions in a month)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: HA injections + Exercise-based rehabilitation (combined treatment)
Number of subjects: 165
Study: 25445314

Group type: EXPERIMENTAL
Intervention: Nurse telephone support (DISPO ED)
Number of subjects: 500000

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 500000
Study: 24223328

Group type: EXPERIMENTAL
Intervention: Lidocaine spray (2 mg/kg)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Morphine spray (0.05 mg/kg)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Ketamine spray (0.5 mg/kg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Normal saline spray (8 puffs)
Number of subjects: 120
Study: 19050634

Group type: EXPERIMENTAL
Intervention: Prospective diary intervention kept by nursing staff during ICU stay
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no diary intervention)
Number of subjects: 36
Study: 17961392

Group type: EXPERIMENTAL
Intervention: Glucosamine hydrochloride (2 times daily for 6 weeks, 1 capsule each time)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Glucosamine sulfate (3 times daily for 6 weeks, 2 capsules each time)
Number of subjects: 143
Study: 15628826

Group type: EXPERIMENTAL
Intervention: rasagiline 1 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: rasagiline 5 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: rasagiline 2 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: rasagiline 10 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: rasagiline 20 mg
Number of subjects: 36

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 36
Study: 11265951

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study: 9554648

Group type: EXPERIMENTAL
Intervention: pHi <7.32
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: pHi >= 7.32
Number of subjects: 19
Study: 8302104

Group type: COMPARATOR
Intervention: Belief/Informational intervention group
Number of subjects: 301

Group type: COMPARATOR
Intervention: Belief intervention
Number of subjects: 301

Group type: COMPARATOR
Intervention: Informational intervention
Number of subjects: 301

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 301
Study: 2657547

Group type: EXPERIMENTAL
Intervention: Epidural administration of epinephrine-morphine-bupivacaine drug combination
Number of subjects: 50
Study: 31748836

Group type: EXPERIMENTAL
Intervention: Conservative oxygen therapy
Number of subjects: 251

Group type: COMPARATOR
Intervention: Usual oxygen therapy
Number of subjects: 251
Study: 31227278

Group type: EXPERIMENTAL
Intervention: Daily subcutaneous 0.20-μg Teriparatide injection for 8 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: No treatment for 8 weeks
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Daily subcutaneous 0.20-μg Teriparatide injection for 8 weeks (after 8 weeks of no treatment)
Number of subjects: 16

Group type: COMPARATOR
Intervention: No treatment for 8 weeks (followed by Teriparatide treatment)
Number of subjects: 16
Study: 27665293

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Neurofeedback (NFB)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Physical Activity (PA)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: All treatments (NFB, MPH, PA)
Number of subjects: 112
Study: 25710943

Group type: EXPERIMENTAL
Intervention: Exercise (EX)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (Con)
Number of subjects: 28
Study: 23520220

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT) intervention for anger management, delivered over 12 weeks
Number of subjects: 179

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT) intervention for anger management
Number of subjects: 179
Study: 21122818

Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 19841527

Group type: EXPERIMENTAL
Intervention: Folic acid 5 mg/d
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Folic acid 15 mg/d
Number of subjects: 80

Group type: COMPARATOR
Intervention: Routine folic acid supplementation 10 mg/d
Number of subjects: 80
Study: 17530984

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) at 20, 27, or 34 Hz for 4 weeks
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) at long muscle lengths
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) at short muscle lengths
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) at lower frequencies
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) training
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Vibration frequency and muscle length during vibration
Number of subjects: 28
Study: 16260422

Group type: EXPERIMENTAL
Intervention: Methimazole therapy for Graves' hyperthyroidism
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Short-term experimental hyperthyroidism in healthy subjects
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: L-thyroxine substitution in hypothyroid patients
Number of subjects: 24
Study: 11821452

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HDC)
Number of subjects: 60
Study: 9799029

Group type: EXPERIMENTAL
Intervention: Potassium supplementation (64 mmol/day of K as slow-release KCl tablets)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control period (no potassium supplementation)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Potassium supplementation
Number of subjects: 55
Study: 7900700

Group type: EXPERIMENTAL
Intervention: 3 x 10(6) IU/day of rIL-2
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 9 x 10(6) IU/day of rIL-2
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 27 x 10(6) IU/day of rIL-2
Number of subjects: 9

Group type: COMPARATOR
Intervention: Calmette-Guérin bacillus locoregional instillation
Number of subjects: 9
Study: 2793707

Group type: EXPERIMENTAL
Intervention: Almitrine (A) 75 mg po
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Almitrine (A)
Number of subjects: 8
Study: 367713

Group type: EXPERIMENTAL
Intervention: Fenbufen 600 mg daily
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Indomethacin 75 mg daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31880246

Group type: EXPERIMENTAL
Intervention: β-D-Mannuronic Acid (M2000)
Number of subjects: 0
Study: 31677528

Group type: EXPERIMENTAL
Intervention: Self-compassion intervention
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Cognitive restructuring intervention
Number of subjects: 119
Study: 29297443

Group type: EXPERIMENTAL
Intervention: Isoniazid preventive therapy (IPT) started at Month 1 after screening for active TB.
Number of subjects: 1030

Group type: COMPARATOR
Intervention: Not applicable (control group not explicitly mentioned).
Number of subjects: 1030
Study: 24524384

Group type: EXPERIMENTAL
Intervention: Supervised exercise targeting back and core muscles, two times per week for 24 weeks
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group continued their usual fitness regimen
Number of subjects: 96
Study: 23729925

Group type: EXPERIMENTAL
Intervention: 5 consecutive nights of sleep restriction (6.5 hours in bed Monday‐Friday)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Healthy sleep duration (10 hours in bed)
Number of subjects: 41
Study: 21302033

Group type: COMPARATOR
Intervention: Zolpidem alone (5 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Zolpidem after pre-treatment with ciprofloxacin (5 mg zolpidem + 500 mg ciprofloxacin)
Number of subjects: 20